Chargement en cours...
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib
The therapeutic options for hepatocellular carcinoma (HCC) have been so far rather inadequate. Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC. Nevertheless, in clinical practice, some patients are discontinuing this drug because of side effec...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Baishideng Publishing Group Co., Limited
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3103800/ https://ncbi.nlm.nih.gov/pubmed/21633647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i19.2450 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|